Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[ABO-incompatible allogeneic bone marrow transplantation].

L Xu1, N Guo, S Wang

  • 1Institute of Hematology, People's Hospital, Beijing Medical University, Beijing 100044.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|November 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of tyrosine kinase activation and granule release through beta-arrestin by CXCRI.

Nature immunology·2001
Same author

Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells.

Cancer research·2000
Same author

Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators.

The Journal of biological chemistry·2000
Same author

The skeletal muscle calcium release channel: coupled O2 sensor and NO signaling functions.

Cell·2000
Same author

Identification of differentially expressed genes in nasopharyngeal carcinoma by means of the Atlas human cancer cDNA expression array.

Journal of cancer research and clinical oncology·2000
Same author

The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation.

Nature cell biology·2000
Same journal

[Advances in ribosome biogenesis and targeted therapies for diffuse large B-cell lymphomas].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
Same journal

[Recent advances in the management of iron deficiency and iron deficiency anemia during pregnancy].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
Same journal

[ALK-positive histiocytosis in adults with undifferentiated uterine sarcoma: a case report].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
Same journal

[Myeloproliferative neoplasm with a homozygous germline SH2B3 mutation: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
Same journal

[Aggressive NK-cell leukemia with CD5(+)CD10(-) monoclonal B cell lymphocytosis and hemophagocytic lymphohistiocytosis: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
Same journal

[Allogeneic hematopoietic stem cell transplantation for RASGRP2 gene-related inherited platelet function disorders: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
See all related articles

ABO-incompatible allogeneic bone marrow transplantation (allo-BMT) is safe, with no adverse effects on engraftment or survival. However, isolated cases of pure red cell aplasia (PRCA) may occur in recipients.

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Science

Context:

  • Allogeneic bone marrow transplantation (allo-BMT) is a critical treatment for various hematologic disorders.
  • ABO incompatibility between donor and recipient poses potential immunohematological challenges.
  • Managing ABO incompatibility is crucial for successful allo-BMT outcomes.

Purpose:

  • To investigate the immunohematological complications associated with ABO-incompatible allogeneic bone marrow transplantation (allo-BMT).
  • To assess the safety and efficacy of ABO-incompatible allo-BMT using specific graft manipulation techniques.

Summary:

  • This study evaluated 61 ABO-incompatible allo-BMTs (38 major, 23 minor) against 61 ABO-compatible controls.
  • Grafts were processed to remove erythrocytes or plasma to mitigate ABO antibodies.

Related Experiment Videos

  • No significant adverse effects on engraftment, GVHD, or survival were observed in ABO-incompatible cases.

    • Impact:

    • ABO-incompatible allo-BMT is a viable and safe option when indicated, with careful management.
    • While generally safe, there's a risk of pure red cell aplasia (PRCA) in specific patient groups (e.g., blood group O recipients).
    • Further research may optimize protocols to minimize PRCA incidence and improve long-term outcomes.